Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov:142:108851.
doi: 10.1016/j.jsat.2022.108851. Epub 2022 Jul 29.

Use of long-acting injectable buprenorphine in the correctional setting

Rosemarie A Martin  1 , Justin Berk  2 , Josiah D Rich  3 , Augustine Kang  4 , John Fritsche  5 , Jennifer G Clarke  6
Affiliations

Use of long-acting injectable buprenorphine in the correctional setting

Rosemarie A Martin et al. J Subst Abuse Treat. 2022 Nov.

Abstract

Background: As overdoses due to opioids rise, medications for opioid use disorder (MOUD) continue to be underemployed, resulting in limited access to potentially life-saving treatment. Substance use disorders are prevalent in individuals who are incarcerated, and these individuals are at increased risk for death postrelease due to overdose. Few jails and prisons offer MOUD and most limit access. Extended-release buprenorphine (XR-BUP), a novel monthly injectable MOUD formulation, could be uniquely poised to address treatment access in correctional settings.

Methods: This study linked a retrospective cohort design of statewide datasets to evaluate the real-world use of XR-BUP. The study included individuals (N = 54) who received XR-BUP while incarcerated from January 2019 through February 2022. The study was conducted at the Rhode Island Department of Corrections, with the nation's first comprehensive statewide correctional MOUD program.

Results: Fifty-four individuals received a combined total of 162 injections during the study period. The study found no evidence of tampering with the injection site, indicating no attempts by participants to remove, hoard, or divert the medication. Sixty-one percent reported at least one adverse effect after injections were received, with an average of 2.8 side effects. Sixty-one percent of those released on XR-BUP engaged in MOUD after release, 30 % continued with XR-BUP.

Conclusions: XR-BUP is feasible and acceptable in correctional settings. XR-BUP addresses administrative concerns of diversion that obstruct lifesaving MOUD and offers another safe and effective treatment option. Further studies and trials should continue to assess this novel medication's ability to treat opioid addiction in the correctional setting and upon release to the community.

Keywords: Access to care; Correctional facilities; Medications for opioid use disorder; XR-buprenorphine.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Nothing declared.

Figures

Figure 1:
Figure 1:
Number of individuals prescribed XR-BUP, the number who discontinued XR-BUP, reasons for discontinuance, and post-release MOUD engagement
See this image and copyright information in PMC

References

    1. Binswanger IA (2013). Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009. Annals of Internal Medicine, 159(9), 592. - PMC - PubMed
    1. Binswanger IA, Blatchford PJ, Mueller SR, & Stern MF (2013). Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. - PMC - PubMed
    1. Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, & Rich J (2018). A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. Drug and Alcohol Dependence, 184, 57–63. - PMC - PubMed
    1. Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, . . . Rolland B (2021). Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. Patient Preference and Adherence, Volume 15, 1259–1267. - PMC - PubMed
    1. Clarke JG, Martin RA, Gresko SA, & Rich JD (2018). The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System. American Journal of Public Health, 108(10), 1323–1325. - PMC - PubMed

Publication types